drugset / Trial / NCT00292734

STILDEP: Zolpidem in Depressive and Dysthimic Patients

NCT00292734

Phase 4 Completed 120 enrolled Sanofi
RandomizedFactorialOpen-labelTreatment

Summary

Primary objective: To show that the combination of Zolpidem + antidepressant therapy is more effective in the treatment of the secondary insomnia of depressive and dysthimic patients than antidepressant therapy alone in the acute phase of the disease.

Timeline

Start
2005-01
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Zolpidem Small molecule